Full metadata record

DC Field Value Language
dc.contributor.authorKim, Eun Hye-
dc.contributor.authorLee, Jongwon-
dc.contributor.authorKwak, Gijung-
dc.contributor.authorJang, Hochung-
dc.contributor.authorKim, Hyosuk-
dc.contributor.authorCho, Haeun-
dc.contributor.authorJang, Yeongji-
dc.contributor.authorChoi, Jiwoong-
dc.contributor.authorChi, Sung Gil-
dc.contributor.authorKim, Kwangmeyung-
dc.contributor.authorKwon, Ick Chan-
dc.contributor.authorYang, Yoosoo-
dc.contributor.authorKim, Sun Hwa-
dc.date.accessioned2024-01-19T12:02:55Z-
dc.date.available2024-01-19T12:02:55Z-
dc.date.created2022-05-12-
dc.date.issued2022-05-
dc.identifier.issn0168-3659-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/115232-
dc.description.abstractUpregulation of oncogenic miRNA21 (miR-21) plays a pivotal role in proliferation, migration and invasion of cancer cells. In addition to cancer cells, tumor-associated macrophages (TAMs) also have high abundance of miR21, which accelerates malignant progression of tumors in the late stages of carcinogenesis. Despite of the protumorigenic functions of miR-21 in TAMs and cancer cells, reliable therapeutic strategies to simultaneously inhibit miR-21 activity in both types of cell have not yet been developed. In this study, we designed a dualtargeting drug delivery system of miR-21 inhibitors that could bind to both tumor cells and macrophages with overexpressed PD-L1 receptors. This peptide-oligonucleotide conjugate (Pep-21) consists of a PDL1-binding peptide covalently linked with an anti-miR-21 inhibitor via click chemistry. Pep-21 was preferentially internalized in both cell types, consequently depleting endogenous miR-21. Our studies found that Pep-21 treatment reduced tumor cell migration, reprogrammed immunosuppressive M2-type TAMs into M1-type macrophages, and restrained tumor progression. Collectively, neutralization of miR-21 activity in both cancer cells and TAMs can be a promising strategy for effective antitumor responses.-
dc.languageEnglish-
dc.publisherElsevier BV-
dc.titlePDL1-binding peptide/anti-miRNA21 conjugate as a therapeutic modality for PD-L1high tumors and TAMs-
dc.typeArticle-
dc.identifier.doi10.1016/j.jconrel.2022.02.031-
dc.description.journalClass1-
dc.identifier.bibliographicCitationJournal of Controlled Release, v.345, pp.62 - 74-
dc.citation.titleJournal of Controlled Release-
dc.citation.volume345-
dc.citation.startPage62-
dc.citation.endPage74-
dc.description.isOpenAccessN-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000783878100001-
dc.identifier.scopusid2-s2.0-85125879435-
dc.relation.journalWebOfScienceCategoryChemistry, Multidisciplinary-
dc.relation.journalWebOfScienceCategoryPharmacology & Pharmacy-
dc.relation.journalResearchAreaChemistry-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.type.docTypeEditorial Material-
dc.subject.keywordPlusIN-VIVO-
dc.subject.keywordPlusCANCER-
dc.subject.keywordPlusMICRORNAS-
dc.subject.keywordPlusOLIGONUCLEOTIDES-
dc.subject.keywordAuthoranti-miRNA delivery-
dc.subject.keywordAuthorPD-L1-
dc.subject.keywordAuthormiR-21-
dc.subject.keywordAuthorB16 melanoma-
dc.subject.keywordAuthorTumor-associated macrophage-
Appears in Collections:
KIST Article > 2022
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE